
Jasper Therapeutics launches with $35mm Series A round to develop HCT compound from Amgen; $14.1mm tranche added
Executive Summary
Jasper Therapeutics Inc. (hematopoietic cell transplants (HCTs) and gene therapies) launched with a $35mm Series A round co-led by Abingworth and Qiming Venture Partners. Surveyor Capital (an equities business of Citadel Capital) and Alexandria Venture Investments also participated. |
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com